Combined use of 1,25-dihydroxyvitamin D3 and dexamethasone promotes osteogenic differentiation of synovial fluid mesenchymal stem cells from human temporomandibular joint

doi:10.3969/j.issn.2095-4344.0477

Abstract

Abstract:

BACKGROUND: Synovial fluid mesenchymal stem cells can be amplified rapidly in vitro and collected by a minimally invasive method. Recent studies have suggested that synovial fluid mesenchymal stem cells have become an important kind of seed cells for bone tissue engineering. Osteogenic differentiation is required to be optimized prior to the application of synovial fluid mesenchymal stem cells in the bone regeneration.
OBJECTIVE: To describe a protocol to generate osteoblast-lineage cells from human synovial fluid mesenchymal stem cells of the temporomandibular joint using a cocktail that includes glutamax, dexamethasone, β-glycerophosphate, vitamin C, 1,25-dihydroxyvitamin D3, and to investigate the effect of 1,25-dihydroxyvitamin D3 and dexamethasone on the osteogenic capacity of synovial fluid mesenchymal stem cells.
METHODS: Synovial fluid mesenchymal stem cells from the human temporomandibular joint were expanded in vitro and cultured in different osteogenic induction media. The mineralization capacity of osteogenic differentiation was evaluated by alizarin red and Von kossa staining. And the osteogenic markers, including ALP, RUNX2 and OCN, were assessed by reverse transcription-PCR.
RESULTS AND CONCLUSION: The mineralization formation increased greatly in the medium with 100 nmol/L dexamethasone and 10 nmol/L 1,25-dihydroxyvitamin D3. The expression of ALP, RUNX2 and OCN was enhanced distinctly in the 1,25-dihydroxyvitamin D3-induced differentiated cells. These findings reveal that appropriate concentration of 1,25-dihydroxyvitamin D3 and dexamethasone can be ideal ingredients to induce the osteogenic differentiation of human synovial fluid mesenchymal stem cells of the temporomandibular joint. Thus, this effective condition can be used to induce the osteogenic differentiation of synovial fluid mesenchymal stem cells for the bone regeneration in the temporomandibular joint.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

Key words: Synovial Fluid, Mesenchymal Stem Cells, Cell Differentiation, Calcitriol, Dexamethasone, Tissue Engineering

CLC Number:

R394.2

Liu Wen-jing, Sun Yang-peng, Zheng You-hua, Zhang Zhi-guang. Combined use of 1,25-dihydroxyvitamin D3 and dexamethasone promotes osteogenic differentiation of synovial fluid mesenchymal stem cells from human temporomandibular joint[J]. Chinese Journal of Tissue Engineering Research, 2018, 22(9): 1443-1449.

Figures/Tables 1

References

[1] Liu F, Steinkeler A. Epidemiology, diagnosis, and treatment of temporomandibular disorders. Dent Clin North Am. 2013; 57(3):465-479.

[2] Gauer RL, Semidey MJ. Diagnosis and treatment of temporomandibular disorders. Am Fam Physician. 2015; 91(6):378-386.

[3] Schek RM, Taboas JM, Hollister SJ, et al. Tissue engineering osteochondral implants for temporomandibular joint repair. Orthod Craniofac Res. 2005;8(4):313-319.

[4] Sun YP, Zheng YH, Liu WJ, et al. Synovium fragment-derived cells exhibit characteristics similar to those of dissociated multipotent cells in synovial fluid of the temporomandibular joint. PLoS One. 2014;9(7):e101896.

[5] Turner AG, Hanrath MA, Morris HA, et al. The local production of 1,25(OH)2D3 promotes osteoblast and osteocyte maturation. J Steroid Biochem Mol Biol. 2014;144 Pt A: 114-118.

[6] Kato H, Ochiai-Shino H, Onodera S, et al. Promoting effect of 1,25(OH)2 vitamin D3 in osteogenic differentiation from induced pluripotent stem cells to osteocyte-like cells. Open Biol. 2015;5(2):140201.

[7] Mostafa NZ, Fitzsimmons R, Major PW, et al. Osteogenic differentiation of human mesenchymal stem cells cultured with dexamethasone, vitamin D3, basic fibroblast growth factor, and bone morphogenetic protein-2. Connect Tissue Res. 2012;53(2):117-131.

[8] Shen M, Luo Y, Niu Y, et al. 1,25(OH)2D deficiency induces temporomandibular joint osteoarthritis via secretion of senescence-associated inflammatory cytokines. Bone. 2013; 55(2):400-409.

[9] Li T, Li H, Li T, et al. MicroRNA expression profile of dexamethasone-induced human bone marrow-derived mesenchymal stem cells during osteogenic differentiation. J Cell Biochem. 2014;115(10):1683-1691.

[10] Ghali O, Broux O, Falgayrac G, et al. Dexamethasone in osteogenic medium strongly induces adipocyte differentiation of mouse bone marrow stromal cells and increases osteoblast differentiation. BMC Cell Biol. 2015;16:9.

[11] Liu W, Sun Y, He Y, et al. IL-1β impedes the chondrogenic differentiation of synovial fluid mesenchymal stem cells in the human temporomandibular joint. Int J Mol Med. 2017;39(2): 317-326.

[12] Bianco P, Robey PG, Simmons PJ. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell. 2008; 2(4):313-319.

[13] Lavi A, Pelled G, Tawackoli W, et al. Isolation and characterization of mesenchymal stromal progenitors from the temporomandibular joint disc. J Tissue Eng Regen Med. 2017;11(5):1553-1561.

[14] Strioga M, Viswanathan S, Darinskas A, et al. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev. 2012;21(14):2724-2752.

[15] Sakaguchi Y, Sekiya I, Yagishita K, et al. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. Arthritis Rheum. 2005;52(8):2521-2529.

[16] Chijimatsu R, Kobayashi M, Ebina K, et al. Impact of dexamethasone concentration on cartilage tissue formation from human synovial derived stem cells in vitro. Cytotechnology. 2018 Jan 19. doi: 0.1007/s10616-018-0191-y. [Epub ahead of print]

[17] Morsczeck C, Reck A, Reichert TE. WNT3A and the induction of the osteogenic differentiation in adipose tissue derived mesenchymal stem cells. Tissue Cell. 2017;49(4):489-494.

[18] Kyllönen L, Haimi S, Säkkinen J, et al. Exogenously added BMP-6, BMP-7 and VEGF may not enhance the osteogenic differentiation of human adipose stem cells. Growth Factors. 2013;31(5):141-153.

[19] Ma X, Zhang X, Jia Y, et al. Dexamethasone induces osteogenesis via regulation of hedgehog signalling molecules in rat mesenchymal stem cells. Int Orthop. 2013;37(7): 1399-1404.

[20] Yuasa M, Yamada T, Taniyama T, et al. Dexamethasone enhances osteogenic differentiation of bone marrow- and muscle-derived stromal cells and augments ectopic bone formation induced by bone morphogenetic protein-2. PLoS One. 2015;10(2):e0116462.

[21] Liu S, Fang T, Yang L, et al. Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the NRF2 signaling pathway. Int J Mol Med. 2018;41(4):2059-2069.

[22] 罗翠芬,彭国光,冯远华,等.激素对种植体骨结合影响的研究进展[J].口腔疾病防治,2017,25(7):473-476.

[23] Rimando MG, Wu HH, Liu YA, et al. Glucocorticoid receptor and Histone deacetylase 6 mediate the differential effect of dexamethasone during osteogenesis of mesenchymal stromal cells (MSCs). Sci Rep. 2016;6:37371.

[24] Takahashi N, Udagawa N, Suda T. Vitamin D endocrine system and osteoclasts. Bonekey Rep. 2014;3:495.

[25] Meyer MB, Benkusky NA, Lee CH, et al. Genomic determinants of gene regulation by 1,25-dihydroxyvitamin D3 during osteoblast-lineage cell differentiation. J Biol Chem. 2014;289(28):19539-19554.

[26] 曾宪莉,赵红宇.1,25-二羟维生素D3在口腔医学领域的研究进展[J].口腔疾病防治,2010,18(2):106-108.

[27] Chen YC, Ninomiya T, Hosoya A, et al. 1α,25-Dihydroxyvitamin D3 inhibits osteoblastic differentiation of mouse periodontal fibroblasts. Arch Oral Biol. 2012;57(5): 453-459.

[28] Song I, Kim BS, Kim CS, et al. Effects of BMP-2 and vitamin D3 on the osteogenic differentiation of adipose stem cells. Biochem Biophys Res Commun. 2011;408(1):126-131.

[29] Hee CK, Nicoll SB. Endogenous bone morphogenetic proteins mediate 1alpha, 25-dihydroxyvitamin D(3)-induced expression of osteoblast differentiation markers in human dermal fibroblasts. J Orthop Res. 2009;27(2):162-168.

[30] Pande VV, Chousalkar KC, Bhanugopan MS, et al. Super pharmacological levels of calcitriol (1,25-(OH)2D3) inhibits mineral deposition and decreases cell proliferation in a strain dependent manner in chicken mesenchymal stem cells undergoing osteogenic differentiation in vitro. Poult Sci. 2015;94(11):2784-2796.

[31] Olivares-Navarrete R, Sutha K, Hyzy SL, et al. Osteogenic differentiation of stem cells alters vitamin D receptor expression. Stem Cells Dev. 2012;21(10):1726-1735.

[32] Nakanishi T, Saito R, Taniguchi M, et al. In vivo determination of vitamin d function using transgenic mice carrying a human osteocalcin luciferase reporter gene. Biomed Res Int. 2013; 2013:895706.

[33] Tarasco M, Laizé V, Cardeira J, et al. The zebrafish operculum: A powerful system to assess osteogenic bioactivities of molecules with pharmacological and toxicological relevance. Comp Biochem Physiol C Toxicol Pharmacol. 2017;197:45-52.

[34] Curtis KM, Aenlle KK, Frisch RN, et al. TAp63γ and ΔNp63β promote osteoblastic differentiation of human mesenchymal stem cells: regulation by vitamin D3 Metabolites. PLoS One. 2015;10(4):e0123642.

[35] Curtis KM, Aenlle KK, Roos BA, et al. 24R,25-dihydroxyvitamin D3 promotes the osteoblastic differentiation of human mesenchymal stem cells. Mol Endocrinol. 2014;28(5):644-658.

[36] Artaza JN, Sirad F, Ferrini MG, et al. 1,25(OH)2vitamin D3 inhibits cell proliferation by promoting cell cycle arrest without inducing apoptosis and modifies cell morphology of mesenchymal multipotent cells. J Steroid Biochem Mol Biol. 2010;119(1-2):73-83.

[37] Yang D, Atkins GJ, Turner AG, et al. Differential effects of 1,25-dihydroxyvitamin D on mineralisation and differentiation in two different types of osteoblast-like cultures. J Steroid Biochem Mol Biol. 2013;136:166-170.